HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

NCT06632093 · clinicaltrials.gov ↗

RECRUITING

Status

84

Enrollment

OTHER

Sponsor class

Conditions

BCLC Stage B Hepatocellular Carcinoma
BCLC Stage C Hepatocellular Carcinoma
Hepatic Arterial Infusion Chemotherapy
Lenvatinib
PD-1
Systemic Therapy

Interventions

PROCEDURE: hepatic artery infusion chemotherapy
DRUG: Lenvatinib + PD-1 monoclonal antibody

Sponsor

First Hospital of China Medical University